vTv Therapeutics Inc.: amends bylaws

What happened vTv Therapeutics Inc. filed a Form 8-K on Oct 6, 2026 reporting that the board approved the adoption of the Company’s Third Amended and Restated By-Laws (the “Amended By-Laws”). The filing states the Amended By-Laws were amended and restated to revise director nomination procedures, the voting standard for stockholder meetings, certain meeting procedures, an exclusive forum provision, and other ministerial and conforming changes. The filing is signed by Paul J. Sekhri, President and Chief Executive Officer.

Key details

• Requires a stockholder seeking to nominate one or more directors at a meeting to deliver reasonable evidence of compliance with Rule 14a-19 no later than 5 business days before the meeting.
• Revises voting standard so that, other than elections of directors, the affirmative vote of a majority of the voting power of the shares cast affirmatively or negatively shall be the act of the stockholders.
• Revises certain meeting procedures to conform to the Delaware General Corporation Law.
• Designates the federal district courts of the United States as the exclusive forum for complaints asserting causes of action arising under the Securities Act of 1933, unless the Company consents in writing to an alternative forum.

Why it may matter This Form 8-K reports Item 5.03: Amendments to articles of incorporation or bylaws, which covers adoption of the Amended By-Laws and the specific governance changes described above. This filing does not show why the insider traded or why the company acted.